What is longevity science?

Longevity science (geroscience) is the study of the biology of aging — identifying the molecular and cellular mechanisms that drive biological aging — and developing interventions that might extend both healthspan (years lived in good health) and lifespan. It is distinct from anti-aging cosmetics or supplements with unproven claims. Evidence-based longevity science focuses on: understanding conserved aging pathways (mTOR, sirtuins, FOXO, IGF-1); interventions proven in rigorous model organisms (caloric restriction, rapamycin, senolytics); and translating these findings into human trials (TAME, ILA, senolytics trials).

Why does mainstream medicine resist longevity science?

Several factors: (1) Regulatory: regulators like the FDA do not recognise "aging" as a disease or indication — meaning drugs cannot be approved to slow aging directly (only for specific diseases). The TAME trial's partial breakthrough — gaining FDA acknowledgment that a drug preventing multiple diseases simultaneously has a plausible pathway — is therefore groundbreaking. (2) Reductionism: medicine is organised around organ systems and disease categories, not around the upstream biology of aging. (3) Short time horizons: clinical trials measure disease outcomes in 5-10 years; aging interventions require longer observation. (4) Commercial: pharmaceutical companies profit from treating age-related diseases individually, not from preventing aging broadly. (5) Historical dismissal: anti-aging has long been associated with quackery — making serious scientists cautious.

What are the 12 Hallmarks of Aging?

Lopez-Otín and colleagues identified 9 hallmarks in 2013 and updated to 12 in Cell 2023, organised into three categories: Primary (initiating) causes: (1) genomic instability — accumulating DNA damage; (2) telomere attrition — shortening of protective chromosome caps; (3) epigenetic alterations — methylation and histone changes disrupting gene expression; (4) loss of proteostasis — failure of protein quality control; (5) disabled macroautophagy — impaired cellular recycling. Antagonistic (responses that become harmful): (6) deregulated nutrient sensing — mTOR, sirtuins, AMPK dysregulation; (7) mitochondrial dysfunction — energy production failure; (8) cellular senescence — zombie cells secreting inflammatory mediators. Integrative (downstream consequences): (9) stem cell exhaustion; (10) altered intercellular communication; (11) chronic inflammation ("inflammaging"); (12) dysbiosis — gut microbiome shifts with aging.

What is rapamycin and why is it interesting for longevity?

Rapamycin (sirolimus) is an mTOR inhibitor — already approved as an immunosuppressant for organ transplantation and as an anti-cancer drug. Its longevity potential comes from: (1) the most reproducible pharmacological lifespan extension across species — worms, flies, mice; (2) remarkable 40% lifespan extension in mice even when started at 20 months (equivalent to ~60 years in humans); (3) mechanistic plausibility — mTOR drives cellular ageing through suppression of autophagy, induction of senescence, and metabolic dysregulation. Multiple small human trials (ILA trial, oral rapamycin in healthy adults) show improvements in immune function and longevity biomarkers. Low-dose intermittent rapamycin (weekly) is increasingly used off-label by longevity-focused clinicians. Risks: immunosuppression, metabolic effects — require monitoring.

What is the TAME trial?

TAME (Targeting Aging with Metformin) — funded by the American Federation for Aging Research (AFAR), led by Dr. Nir Barzilai at Einstein College of Medicine, launched 2022 — is the first human clinical trial explicitly designed to slow the biological process of aging. It tests metformin (the world's most-prescribed diabetes drug) in 3,000 non-diabetic adults aged 65-79 over 6 years, measuring the composite endpoint of time to first occurrence of major age-related diseases (cancer, cardiovascular disease, dementia, disability, death). Its most profound significance: the FDA agreed that preventing multiple age-related diseases simultaneously could be a valid drug endpoint — a regulatory landmark that opens the path for future longevity drugs.

What role does exercise play in longevity?

Exercise is the most evidence-based longevity intervention in humans with the largest absolute risk reduction of any single lifestyle factor — reducing all-cause mortality by approximately 30-35% (VO2max is one of the strongest predictors of longevity). Mechanisms: improved mitochondrial biogenesis (PGC-1α activation); reduced senescent cell burden; anti-inflammatory effects; IGF-1/mTOR modulation; telomere maintenance; improved insulin sensitivity; neurogenesis (BDNF). Both aerobic exercise and resistance training independently contribute to longevity. Zone 2 training (steady-state moderate intensity — lactate threshold) is increasingly recognised as the most important longevity-relevant exercise modality, combined with high-intensity intervals for VO2max.

Is longevity science different from anti-aging medicine?

Yes — fundamentally. The anti-aging industry (cosmetics, some supplements, unproven therapies) is largely driven by commercial incentives with weak or absent clinical evidence. Evidence-based longevity science is characterised by: hypothesis-driven research in peer-reviewed journals (Nature, Cell, Science); validated animal models with rigorous controls; human trials with hard endpoints (not just surrogate biomarkers without clinical correlation); transparent reporting of negative results; and engagement with regulatory frameworks (FDA IND applications). GMJ News covers evidence-based longevity science — critically evaluating claims, distinguishing proven interventions from speculative ones, and tracking the clinical trial pipeline.

How does GMJ News cover longevity science?

GMJ News covers: the Hallmarks of Aging framework and new discoveries in aging biology; clinical trial updates (TAME, ILA, senolytics trials); longevity biotechnology developments and funding; epigenetic clock research; nutrition and exercise interventions with longevity evidence; regulatory developments (FDA aging indications); and critical evaluation of longevity claims. The GMJ Longevity hub bridges the gap between cutting-edge geroscience and clinical practice — for Georgian healthcare professionals, researchers and educated general readers interested in the science of aging.

Home › Topics › Longevity Science

Longevity Science

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Longevity science — the study of biological mechanisms driving aging and interventions that might extend both healthspan and lifespan — has emerged as one of the fastest-growing sectors in biomedical research, with over $5 billion in annual investment and a global community actively challenging the assumption that aging is biologically inevitable, culminating in the identification of the 12 Hallmarks of Aging (Lopez-Otín 2023) as the upstream drivers of virtually every non-communicable disease (WHO/Nature 2023). Mainstream medicine has historically treated aging as a backdrop rather than a modifiable target — but the discovery of conserved longevity pathways (mTOR, sirtuins, FOXO, IGF-1), the development of senolytics (drugs clearing senescent cells) and the launch of the TAME trial (the first human clinical trial using a drug to slow aging itself) are rapidly repositioning geroscience as the most consequential frontier in twenty-first century medicine. GMJ News covers longevity at the rigorous intersection of basic science and clinical translation.

Key messages

12 Hallmarks of Aging — the scientific framework

The 2023 update to the Hallmarks of Aging (Lopez-Otín et al., Cell 2023) identifies 12 interconnected biological processes driving aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis. These hallmarks are the upstream causes of virtually all age-related NCDs.

Aging is a modifiable biological process

Multiple genetic, pharmacological and dietary interventions extend healthspan and lifespan in model organisms — from caloric restriction (30-40% lifespan extension in rodents) to rapamycin (40% extension even started in late-life mice). Geroscience now treats aging as a targetable process rather than an inevitable backdrop.

Senolytics — clearing senescent cells

Senolytic drugs (dasatinib + quercetin, fisetin, navitoclax) selectively eliminate senescent cells — dysfunctional cells that accumulate with age and drive chronic inflammation ("inflammaging"). Phase 2 trials show senolytics reduce senescence biomarkers in humans; Phase 3 trials for multiple age-related conditions are underway.

Rapamycin and mTOR — most robust animal longevity drug

Rapamycin (inhibiting mTOR complex 1) is the most reproducible pharmacological intervention extending lifespan across species — including 40% extension in mice even when started at equivalent of age 60. The ILA (Interventions in Aging trial) and multiple trials in humans are evaluating weekly low-dose rapamycin for immune function, cognition and longevity biomarkers.

TAME trial — first aging drug trial in humans

The TAME (Targeting Aging with Metformin) trial — funded by AFAR, launched 2022 — is the first human clinical trial designed specifically to slow biological aging, testing whether metformin can delay the onset of multiple age-related diseases simultaneously. Its FDA approval as a longevity trial precedent is as significant as the science itself.

Epigenetic clocks — measuring biological age

Epigenetic aging clocks (Horvath clock, GrimAge, DunedinPACE) measure DNA methylation patterns to estimate biological age — often diverging substantially from chronological age. These clocks are the primary biomarker endpoints for longevity interventions in human trials and are increasingly used to measure the impact of lifestyle, diet and drugs on aging rate.

Key statistics

Hallmarks of Aging (Lopez-Otín Cell 2023 — updated from 9 in 2013)

Nature/Cell 2023

$5B+

annual investment in longevity biotechnology globally (2023)

Longevity.Technology/WHO

40%

lifespan extension in mice with rapamycin (started at mid/late life)

Harrison et al. Nature 2009

TAME

first human trial testing a drug to slow aging (metformin, AFAR/Einstein)

AFAR 2022

2050

year global population over 60 will double to 2.1 billion (WHO)

WHO 2023

150+

longevity biotech companies active globally (2024)

Longevity Industry 2024

12 Hallmarks of Aging — Lopez-Otín Cell 2023

Source: Lopez-Otín et al. Cell 2023. Updated from 9 hallmarks (2013); added disabled autophagy, dysbiosis, chronic inflammation.

Glossary of key terms

Healthspan vs lifespan
WHO/GeroscienceLifespan: total duration of life. Healthspan: the period of life spent in good health and functional independence. Longevity science increasingly targets healthspan extension — compressing morbidity into the final months rather than extending years of disability. In model organisms, some interventions (caloric restriction, rapamycin) extend both.

mTOR (mechanistic target of rapamycin)
Cell/NatureA central cellular nutrient-sensing kinase — integrating signals from amino acids, growth factors and energy status to regulate cell growth, autophagy and senescence. mTOR complex 1 (mTORC1) is hyperactivated with aging, driving cellular hypertrophy and suppressing autophagy. Rapamycin inhibits mTORC1, restoring youthful cellular maintenance.

Cellular senescence
WHO/GeroscienceA cell state — triggered by DNA damage, oncogene activation or oxidative stress — where cells cease dividing but resist apoptosis. Senescent cells accumulate with age and secrete a pro-inflammatory cocktail (SASP — senescence-associated secretory phenotype) that damages neighbouring tissues and drives systemic inflammaging.

Senolytics
Nature MedicineDrugs that selectively eliminate senescent cells — exploiting their anti-apoptotic dependencies. First-generation: dasatinib (BCR-Abl inhibitor) + quercetin (flavonoid); fisetin (flavonoid); navitoclax (BCL-2/BCL-xL inhibitor). Phase 2 trials: improvement in physical function in idiopathic pulmonary fibrosis, diabetic kidney disease, frailty. Multiple Phase 3 trials ongoing.

NAD+ and sirtuins
Nature/CellNAD+ (nicotinamide adenine dinucleotide) — an essential coenzyme — declines approximately 50% between ages 40-60. Sirtuins (SIRT1-7) are NAD+-dependent deacylases regulating DNA repair, mitochondrial biogenesis and inflammation. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) raise NAD+ levels in humans — in trials for metabolic and cognitive aging endpoints.

Epigenetic clocks
Horvath/HannumDNA methylation-based biomarkers of biological age — the Horvath clock (2013), GrimAge (2019) and DunedinPACE measure biological aging rate from blood or tissue samples. GrimAge strongly predicts mortality, cancer, cardiovascular disease and Alzheimer's independent of chronological age. These clocks are the primary endpoints for longevity intervention trials in humans.

Caloric restriction (CR)
WHO/NIAReducing calorie intake by 20-40% without malnutrition — the most reproducible lifespan extension intervention across species (yeast, worms, flies, rodents, primates). The CALERIE trial (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) — first randomised human CR trial — showed 2 years of 12% CR significantly improved cardiometabolic risk and slowed biological aging (DunedinPACE clock).